CDKN2A and astrocytoma (excluding glioblastoma): IDH-mutant astrocytomas with homozygous CDKN2A deletion showed lower LINE-1 methylation levels than IDH-mutant astrocytomas without complete CDKN2A loss (Fig. 2b).